TEMPEST THERAPEUTICS INC (TPST) Stock Price, Forecast & Analysis
NASDAQ:TPST • US87978U2078
TPST Key Statistics, Chart & Performance
The current stock price of TPST is 2.4 USD. In the past month the price decreased by -21.82%. In the past year, price decreased by -78.54%.
TPST Technical Analysis
TPST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TPST. The financial health of TPST is average, but there are quite some concerns on its profitability.
TPST Financial Highlights
Over the last trailing twelve months TPST reported a non-GAAP Earnings per Share(EPS) of -10.05. The EPS increased by 50.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -210.49% | ||
| ROE | -568.14% | ||
| Debt/Equity | 0 |
TPST Forecast & Estimates
7 analysts have analysed TPST and the average price target is 11.22 USD. This implies a price increase of 367.5% is expected in the next year compared to the current price of 2.4.
TPST Ownership
TPST Latest News, Press Relases and Analysis
TPST Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TPST
Company Profile
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Company Info
TEMPEST THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 400
Brisbane California CALIFORNIA US
CEO: Louis Arcudi
Employees: 21
Phone: 14157988589
TEMPEST THERAPEUTICS INC / TPST FAQ
What does TPST do?
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
What is the stock price of TEMPEST THERAPEUTICS INC today?
The current stock price of TPST is 2.4 USD. The price decreased by -1.23% in the last trading session.
What is the dividend status of TEMPEST THERAPEUTICS INC?
TPST does not pay a dividend.
What is the ChartMill technical and fundamental rating of TPST stock?
TPST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of TPST stock?
TEMPEST THERAPEUTICS INC (TPST) has a market capitalization of 31.68M USD. This makes TPST a Nano Cap stock.
What is the next earnings date for TPST stock?
TEMPEST THERAPEUTICS INC (TPST) will report earnings on 2026-03-25, after the market close.